[Immunological regulations of dendritic cell in abnormal scarring tissue].
OBJECTIVE
To investigate the relationship between dendritic cell(DC) and pathogenesis of abnormal scar.


METHODS
The content of HLA-DR and CD1a molecules of DC, in 6 samples of hypertrophic scar (HS), keloid (K) and normal skin, were determined with the stain of avidin-biotin-peroxidase complex method (ABC). The effect of Triamcinolone Acetonide was evaluated with the measurement of the HLA-DR and CD1a molecules of DC in the epidermis of the HS.


RESULTS
1. The amounts of HLA-DR molecules of the positive DC were 806.67 +/- 101.72 and 870.00 +/- 134.24 in the HS and the K respectively, significantly higher than the controlled normal skin (510.01 +/- 45.17, P < 0.05). HLA-DR molecules showed an abnormal expression in the Kerationcytes and fibroblasts. 2. The amounts of CD1a molecules of the positive DC were 700.00 +/- 97.23 and 780.00 +/- 104.47 in the HS and the K respectively, significantly higher than the controlled normal skin (521.24 +/- 57.87)(P < 0.05). 3. The amounts of the HLA-DR molecules positive DC, in the positive kerationcytes and fibroblasts of hypertrophic scar, treated by Triamcinolone Acetonide, were 476.67 +/- 70.02 and 447.76 +/- 90.03 (P < 0.05) for 3 days and 7 days treatment respectively, significantly lower than the control. The amounts of CD1a molecules positive DC in the epidermis of hypertrophic scar with the injection of Triamcinolone Acetonide were significantly lower in 3 days and 7 days treatment (456.36 +/- 82.88 and 397.18 +/- 99.36, P < 0.05).


CONCLUSIONS
1. The results, with the high expression of HLA-DR and CD1a molecules, indicate that the HS and the K may have strong immune reactions. 2. Triamcinolone Acetonide may decrease the immune reactions of the HS, through the inhibition of the expressions of HLA-DR and CD1a molecules in the dendritric cell.
Chen
D
D
Research Center of Plastic Surgery, 3rh Hospital, Beijing University, Beijing 100083.
Bao
W
W
Wang
Q
Q
D017439:Cicatrix, Hypertrophic / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D003713:Dendritic Cells / Q000276:immunology*; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D012867:Skin / Q000166:cytology / Q000276:immunology
D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors